Ardelyx delivered an outstanding first quarter in 2025, with total revenue reaching $74.1 million, a 61% increase year-over-year. This growth was primarily fueled by strong sales of IBSRELA and XPHOZAH, demonstrating the company's commercial strategy and market momentum.
Total revenue for Q1 2025 was $74.1 million, a 61% increase compared to Q1 2024.
IBSRELA net product sales revenue reached $44.4 million, growing approximately 57% year-over-year.
XPHOZAH net product sales revenue was $23.4 million, with net sales revenue excluding returns reserve release growing 30% compared to Q1 2024.
The company ended Q1 2025 with $214.0 million in cash, cash equivalents, and investments.
Ardelyx expects full-year 2025 U.S. net product sales revenue for IBSRELA to be between $240.0 million and $250.0 million.
Analyze how earnings announcements historically affect stock price performance